What is the current United States Insulin Drugs And Delivery Devices Market size?

In 2024, the United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion. Read More

Who are the key players in United States Insulin Drugs And Delivery Devices Market?

Novo Nordisk, Medtronics, Sanofi, Eli Lily and Ypsomped are the major companies operating in the United States Insulin Drugs And Delivery Devices Market. Read More

What years does this United States Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the United States Insulin Drugs And Delivery Devices Market size was estimated at USD 19.17 billion. The report covers the United States Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

US Insulin Drugs & Delivery Devices Market

US Insulin Drugs & Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers United States Insulin Drugs and Delivery Devices Market Companies and it is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

US Insulin Drugs & Delivery Devices Industry Overview

The United States Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Recently, mergers and acquisitions between the players have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.